virus

(redirected from parainfluenza virus)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia, Wikipedia.
Related to parainfluenza virus: adenovirus, enterovirus, croup, rhinovirus, respiratory syncytial virus, vaccine virus
See: disease
References in periodicals archive ?
Control of an outbreak of human parainfluenza virus 3 in hematopoietic stem cell transplant recipients.
Clinical and molecular epidemiology of human parainfluenza virus 4 infections in Hong Kong: subtype 4B as common as subtype 4A.
This patent further validates the unique and pioneering nature of the host-targeting approach used by DAS181 for the potential therapy and prophylaxis of any and all strains of influenza and parainfluenza virus," said David Wurtman, MD, MBA, VP of Corporate Development of NexBio.
double dagger]) Influenza virus A (n = 2), parainfluenza virus 3 (n = 2), rhinovirus (n = 2), metapneumovirus (n = 1), coronavirus OC43 (n = 1).
The majority of the Company's programs are live vaccines against viral infections, including influenza, parainfluenza virus (PIV) (the cause of croup), cytomegalovirus (CMV), genital herpes and respiratory syncytial virus (RSV).
To determine the presence of other respiratory viruses in this patient, the EV-104-positive specimen was tested by using realtime PCR for any of 17 other viruses (human metapneumovirus, respiratory syncytial virus, human parainfluenza virus types 1-4, human bocavirus, human coronavirus [229E, OC43, HKU1, NL63], influenza virus [A, pandemic (H1N1) 2009, B, C], human adenovirus, and HRV).
In addition, DAS181 also has the potential for prophylaxis and treatment of influenza-like illness due to other respiratory viruses, including the parainfluenza virus which may cause serious respiratory illness similar to influenza for which there is no approved vaccine or therapeutic.
Fludase(R) effectively inhibits numerous strains of influenza and parainfluenza virus nonclinical models.
today announced that it has begun dosing at-risk children six months to 24 months of age in a Phase 1 trial of a vaccine designed to help prevent respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV-3) infections, two of the most important causes of lower respiratory tract illness and hospitalization in infants and young children.
Multiplex PCR for respiratory viruses (Fast-track Diagnostics, Junglinster, Luxembourg) was conducted to detect influenza A (including pandemic [H1N1] 2009) and B viruses; respiratory syncytial virus; human metapneumovirus; HBoV; parainfluenza virus 1-4; human coronaviruses HKU1, NL63, 229E, and OC43; human rhinoviruses; human enteroviruses and parechoviruses; and adenoviruses.
We submitted data to the FDA to expand our label indication for FluMist(R) (Influenza Virus Vaccine Live, Intranasal); we entered into an agreement with Infinity Pharmaceuticals to develop cancer drugs focused on two of the most attractive targeted therapy opportunities in cancer research today; we completed a Phase 3 study with our next-generation monoclonal antibody to prevent respiratory syncytial virus (RSV); and we initiated clinical testing with several new compounds, including those targeting lupus, RSV, parainfluenza virus type 3, B-cell lymphomas, and avian influenza viruses.
The respiratory infections panel detects bacterial and viral pathogens associated with respiratory infections and includes targets for the following: adenovirus (types 3, 4, 7, 21), coxsackievirus, echovirus, human metapneumovirus (types A and B), influenza virus (types A and B), parainfluenza virus (types 1-4), respiratory syncytial virus (types A and B), rhinovirus, Acinetobacter baumannii, Chlamydophila pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Legionella pneumophila, Mycoplasma pneumoniae, Neisseria meningitidis, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus pneumoniae, and Streptococcus pyogenes (group A).